NYSE:PFEPharmaceuticals
Pfizer (PFE) Rides MRNA Cancer Optimism On A Valuation That Still Looks Modest
Pfizer (PFE) moved back onto investor watchlists after Merck and Moderna reported positive Phase 3 results for an mRNA melanoma treatment, lifting sentiment toward companies with oncology focused mRNA pipelines.
See our latest analysis for Pfizer.
Across 2026, Pfizer’s share price has shifted from COVID reset concerns to renewed interest in its pipeline, with a 30 day share price return of 11.43% and a 1 year total shareholder return of 15.54%. Short term momentum is building, although the 3...